Add BrightSurf on Google Email

Diamonds are forever: Scientists develop microscopic calibration tool with fluorescent nanodiamonds

Researchers at the University of Illinois created a novel device using microscopic fluorescent diamonds to calibrate sensitive microscopy systems. The nanodiamonds' stability and longevity make them ideal as a 'first-aid kit' for microscopes, allowing for easy reuse and quality control.

SourceBeckman Institute for Advanced Science and Technology·JournalPhotonics Research·TypeImaging analysis·DateNov 5, 2021

Molecular imaging suggests Long-COVID symptoms may be caused by fatigue, not regional brain dysfunction

A recent study suggests that Long-COVID symptoms, such as cognitive deficits and fatigue, may be attributed to fatigue rather than pathological changes in the brain. Neuroimaging results showed no significant differences in cerebral glucose metabolism or brain pathology between patients with long-COVID and healthy controls.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateOct 29, 2021

Light in, sound out: photoacoustic probe helps find and fight Wilson's disease and other maladies

Researchers developed a non-toxic, small-molecule probe that provides real-time visualization of disease progression, overcoming limitations of MRI and PET imaging. The probe binds copper ions and detects dysregulated levels, accurately identifying Wilson's disease and other maladies.

SourceBeckman Institute for Advanced Science and Technology·JournalProceedings of the National Academy of Sciences·TypeRandomized controlled/clinical trial·DateSep 30, 2021

Newly approved PET imaging agent solves clinical dilemmas in breast cancer patients

A new PET imaging agent has been shown to solve 87% of diagnostic dilemmas in breast cancer patients, providing valuable information for personalized treatment decision-making. The agent's ability to visualize estrogen receptor expression across the body may improve patient outcomes and support broader implementation in clinical practice.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·TypeImaging analysis·DateSep 29, 2021

New radionuclide therapy identified for HER2-positive breast cancer patients

A promising radionuclide treatment has been identified for HER2-positive breast cancer patients, combining radioactive iodine therapy with single-domain antibodies targeting the HER2 antigen. The treatment demonstrates safety and efficacy in a phase I study, paving the way for further clinical development.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·TypeRandomized controlled/clinical trial·DateSep 28, 2021

Modern simulations could improve MRIs

Researchers at Rice University have refined models to analyze gadolinium-based contrast agents, which are used in 40% of MRIs worldwide. The team's goal is to design better and more customizable contrast agents that improve image quality while minimizing risks.

SourceRice University·JournalPhysical Chemistry Chemical Physics·TypeComputational simulation/modeling·DateSep 20, 2021

A fast, accurate system for quickly solving stubborn RNA structures from pond scum, the SARS-CoV-2 virus and more

A new system developed at Stanford University and SLAC National Accelerator Laboratory determines the 3D structures of RNA-only molecules with high resolution, applying it to a ribozyme from pond scum and a piece of viral RNA from SARS-CoV-2. The study reveals tiny pockets in the viral RNA that could be targeted for COVID-19 treatments.

SourceDOE/SLAC National Accelerator Laboratory·JournalNature·TypeImaging analysis·DateAug 11, 2021

PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regions

A phase III clinical trial validates the effectiveness of 18F-DCFPyL in detecting and localizing recurrent prostate cancer, achieving high positive predictive values across various regions. The study's results support the use of PSMA-targeted radiotracers as the most sensitive and accurate agents for imaging prostate cancer.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 15, 2021

Immuno-PET can give physicians early insight into tumor response to targeted therapy

Researchers have developed Immuno-PET, a technique that visualizes changes in different cancer receptors within tumors during targeted therapies, enabling early evaluation of treatment effectiveness and prediction of response. This can help physicians select the most effective treatment for patients with cancer.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMar 12, 2021

The Journal of Nuclear Medicine celebrates 60 years of research

The Journal of Nuclear Medicine has published a special supplement commemorating six decades of leadership in the field, featuring influential manuscripts that shaped the future of medicine. The supplement highlights landmark papers on PET, Anger camera, and fusion PET/CT, as well as the journal's past editors and associate editors.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 10, 2020

Using light's properties to indirectly see inside a cell membrane

Researchers have developed a new imaging technique called single-molecule orientation localization microscopy (SMOLM) that allows them to distinguish between different phases of lipid molecules in cell membranes. This technique uses fluorescent probes to directly 'see' the probe's orientation and determine its chemical composition.

SourceWashington University in St. Louis·JournalAngewandte Chemie International Edition·DateAug 25, 2020

SNMMI Image of the Year: Super-agers show resistance to tau and amyloid accumulation

Research at SNMMI 2020 Annual Meeting found super-agers have lower tau and amyloid pathology associated with neurodegeneration. This enables them to maintain their cognitive skills even at advanced ages. The study suggests a potential pathway for successful aging and developing novel treatments to tackle age-related diseases.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 15, 2020

New theranostic agents show efficacy in prostate cancer treatment in preclinical studies

Researchers developed a novel radioiodinated PSMA-targeting radiopharmaceutical that can be produced in high yields without generating volatile byproducts. The agent shows exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies, targeting prostate-specific membrane antigen (PSMA).

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 13, 2020